Clinical T Cell Receptor Repertoire Deep Sequencing and Analysis: An Application to Monitor Immune Reconstitution Following Cord Blood Transplantation by Gkazi, AS et al.
ORIGINAL RESEARCH
published: 05 November 2018
doi: 10.3389/fimmu.2018.02547






Banc de Sang i Teixits, Spain
Emmanuel Clave,




†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Alloimmunity and Transplantation,
a section of the journal
Frontiers in Immunology
Received: 18 June 2018
Accepted: 16 October 2018
Published: 05 November 2018
Citation:
Gkazi AS, Margetts BK,
Attenborough T, Mhaldien L,
Standing JF, Oakes T, Heather JM,
Booth J, Pasquet M, Chiesa R,
Veys P, Klein N, Chain B, Callard R
and Adams SP (2018) Clinical T Cell
Receptor Repertoire Deep
Sequencing and Analysis: An
Application to Monitor Immune




Clinical T Cell Receptor Repertoire
Deep Sequencing and Analysis: An
Application to Monitor Immune
Reconstitution Following Cord Blood
Transplantation
Athina Soragia Gkazi 1†, Ben K Margetts 1,2,3†, Teresa Attenborough 1,3, Lana Mhaldien 4,
Joseph F. Standing 1,5, Theres Oakes 6, James M. Heather 6, John Booth 2,
Marlene Pasquet 7, Robert Chiesa 8, Paul Veys 8, Nigel Klein 1,9, Benny Chain 6,
Robin Callard 1,3 and Stuart P. Adams 1,4*
1 Infection, Immunity and Inflammation Section, Great Ormond Street Institute of Child Health, University College London,
London, United Kingdom, 2Digital Research Environment, Great Ormond Street Hospital for Children NHS Foundation Trust,
London, United Kingdom, 3Centre for Computation, Mathematics, and Physics in the Life Sciences and Experimental
Biology (CoMPLEX), University College London, London, United Kingdom, 4 SIHMDS-Haematology, Great Ormond Street
Hospital for Children NHS Foundation Trust, London, United Kingdom, 5 Pharmacy Department, Great Ormond Street
Hospital for Children NHS Foundation Trust, London, United Kingdom, 6Division of Infection and Immunity, University College
London, London, United Kingdom, 7 Le Centre Hospitalier Universitaire de Toulouse, Toulouse, France, 8Department of
Blood and Marrow Transplantation, Great Ormond Street Hospital for Children NHS Foundation Trust, London,
United Kingdom, 9 Infectious Diseases Department, Great Ormond Street Hospital for Children NHS Foundation Trust,
London, United Kingdom
Spectratyping assays are well recognized as the clinical gold standard for assessing the
T cell receptor (TCR) repertoire in haematopoietic stem cell transplant (HSCT) recipients.
These assays use length distributions of the hyper variable complementarity-determining
region 3 (CDR3) to characterize a patient’s T cell immune reconstitution post-transplant.
However, whilst useful, TCR spectratyping is notably limited by its resolution, with
the technique unable to provide data on the individual clonotypes present in a
sample. High-resolution clonotype data are necessary to provide quantitative clinical
TCR assessments and to better understand clonotype dynamics during clinically
relevant events such as viral infections or GvHD. In this study we developed and
applied a CDR3 Next Generation Sequencing (NGS) methodology to assess the
TCR repertoire in cord blood transplant (CBT) recipients. Using this, we obtained
comprehensive TCR data from 16 CBT patients and 5 control cord samples at Great
Ormond Street Hospital (GOSH). These were analyzed to provide a quantitative
measurement of the TCR repertoire and its constituents in patients post-CBT. We
were able to both recreate and quantify inferences typically drawn from spectratyping
data. Additionally, we demonstrate that an NGS approach to TCR assessment can
provide novel insights into the recovery of the immune system in these patients.
We show that NGS can be used to accurately quantify TCR repertoire diversity
and to provide valuable inference on clonotypes detected in a sample. We serially
assessed the progress of T cell immune reconstitution demonstrating that there
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is dramatic variation in TCR diversity immediately following transplantation and that the
dynamics of T cell immune reconstitution is perturbed by the presence of GvHD. These
findings provide a proof of concept for the adoption of NGS TCR sequencing in clinical
practice.
Keywords: T cell, haematopoietic stem cell transplant, next generation sequencing, T cell receptor, CDR3,
clonotypes, immune reconstitution
INTRODUCTION
Haematopoietic stem cells transplantation (HSCT) utilizes three
different stem cell sources; Bone Marrow (BMT), Peripheral
Blood (PBSCT) or Umbilical Cord (CBT). The stem cell choice
usually depends on availability, underlying disease, and clinical
status (1). Initial HSCTs were carried out using bone marrow
as a stem cell source, but in 1989, Broxmeyer and colleagues
demonstrated that cord blood has similar attributes to bone
marrow and contains significant numbers of progenitor cells,
and suggested cord blood as a possible alternative source to
bone marrow in transplantation (2). The first successful CBT was
performed by Dr. Eliane Gluckman of Hospital St. Louis, Paris,
France in a 5-years-old boy suffering from Fanconi’s Anemia (3).
Since then CBT has been widely used as a treatment for many
diseases, with results from the Cord Blood Transplantation Study
(COBLT) demonstrating the high uptake of CBT in the US (4).
Similarly, since the incorporation of CBT into standard practice
in the UK was recommended (5, 6), the number of CBTs has
increased (7).
CBT has been used with considerable success for the treatment
of malignant diseases (8), primary immunodeficiencies (9), and
metabolic disorders (10). Importantly, it has also been shown to
result in less graft vs. host disease (GvHD) compared with adult
BMT donors (allowing for the degree of HLA mismatch; (11)).
Since the speed at which the immune system recovers after HSCT
has a direct bearing on outcome (12) and given that CBT (with
in vivo T cell depletion) has been shown to result in impaired
T cell immune reconstitution (13), we recently demonstrated
that the omission of serotherapy can lead to a rapid thymic-
independent T cell expansion following CBT (14). These rapidly
expanding naïve T lymphocytes, particularly CD4+ T cells, have
generated considerable interest as it has been shown that they can
differentiate into viral-specific T cells within 2 months and are
able to clear viral infections (14). Rapid recovery of the CD4+ T
cells is associated with less transplant related mortality (15). In
addition, it has been demonstrated in vitro that CBT-derived T
cells are able to mediate a more potent anti-leukaemic effect than
adult T cells (16), which is also apparent in vivo in acute myeloid
leukemia patients undergoing transplantation in the presence of
minimal residual disease (17, 18). Since immune reconstitution
following HSCT is so important for both a successful short-
term and long-term outcome, with regards to GvL, GvHD, and
response to viral infection, comprehensive methodologies are
needed to better assess this process.
Measuring immune reconstitution following CBT using
immunophenotyping with appropriate markers and using
molecular quantification of T cell receptor excision circles
(TRECs) has proved to be useful in assessing thymic-
dependent and independent T cell recovery following CBT
(14). Additionally, the assessment of the T cell receptor (TCR)
repertoire has been carried out using T cell spectratyping (14).
With the advent of Next Generation Sequencing (NGS) it is
now possible to analyse the TCR repertoire in much greater
depth to identify individual TCR clones and sequences (19, 20).
We questioned whether this emerging NGS technology could
be established to more efficiently provide TCR repertoire data
from cord blood units used for CBT. We also aimed to develop
methods for measuring TCR repertoire diversity and to identify
relationships between these measurements and clinical outcomes




This study involved the use of excess diagnostic blood taken
from patients at Great Ormond Street Hospital and was
anonymised prior to use. The study was approved by the
National Research Ethics Service, NRES Committee London—
Bloomsbury (05/Q0508/61) for “Cellular immune reconstitution
following haematopoietic stem cell transplantation.” Thirty-
nine samples were analyzed from 5 control cord samples (not
used for transplantation in this study) and 16 Great Ormond
Street Hospital (GOSH) patients. Additionally, due to the
difficulty in obtaining age-matched pediatric controls, 58 adult
control PBMC samples were analyzed for later comparison
with control cord data. The median age at transplant was 2
years and 1 month and the patients ranged from 0.4 to 7.7
years old. Underlying conditions included a number of different
primary immunodeficiencies (SCID, Wiscott Aldrich Syndrome,
and MHC Class II deficiency), hematological malignancies
(ALL, AML, and JMML) and one metabolic disorder (Hunter
Syndrome). All patients were treated with allo-CBT and sampling
was performed at multiple time points following transplantation
(Table 1). Peripheral blood mononuclear cells were isolated from
10ml of healthy adult volunteer blood. Samples were handled in




Routine immunophenotyping was carried out to measure T cell
numbers and naïve/memory T cells as previously described (21)
T cell receptor spectratyping (22) was carried out using the same
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TABLE 1 | Patient characteristics for all transplanted patients in the study.
Patient Disease Age group at Tx (years) Sampling Time Points (Months) GvHD Grade Conditioning Mortality
A HM 1-2 2, 3, 6, 12 III Myeloablative1 Deceased
B PID 1-2 1, 2 I Reduced Intensity Alive
C HM 2-5 0.5 III Myeloablative4 Deceased
D PID 0-1 1 I Reduced Intensity Alive
E HM 0-1 1 II Myeloablative3 Alive
F PID 1-2 3, 19 I Reduced Intensity Alive
G HM 1-2 1 II Myeloablative1 Alive
H PID 5-10 2, 6, 12 II Reduced Intensity Alive
I HM 1-2 2, 4, 6, 12 IV Myeloablative1 Alive
J HM 5-10 1 IV Myeloablative3 Deceased
K HM 2-5 1, 3 0 Myeloablative1 Alive
L PID 1-2 1, 2, 3, 12, 22 II Reduced Intensity Alive
M PID 0-1 1, 2, 6, 22 II Reduced Intensity Alive
N Metabolic 2-5 1, 3 0 Myeloablative2 Alive
O HM 2-5 2, 12 II Myeloablative1 Alive
P PID 2-5 1, 2, 17, 30 II Reduced Intensity Alive
“GvHD grade” refers to the maximum GvHD grade the patient exhibited. Patient ages at transplant were grouped into 0-1, 1-2, 2-5 or 5-10 years old. Sampling time points refers to the
month post-CBT that the sample was taken on. Myeloablative conditioning comprised ofbusulfan/cyclophosphamide/melphalan1 , busulfan/fludarabine2, treosulfan/fludarabine/thiotepa3
or busulfan/cyclophosphamide4 . Reduced intensity conditioning consisted of treosulfan/fludarabine.
starting RNA sample as for the NGS experiments. Quantification
of TRECs was carried out on DNA extracted from the same
starting sample as used for the NGS experiments and using
previous published methods (21).
Sample Preparation
Peripheral Blood Mononuclear Cells (PBMCs) were isolated
from the blood samples and RNA was extracted using the Qiagen
RNA blood Mini kit (Qiagen, 52304). RNA was subsequently
treated with RQ1 DNase (Promega) following manufacturer’s
instructions to remove any residual genomic DNA.
Library Preparation
Library preparation was based on a protocol for quantitative
TCR sequencing. Full details of the method have been recently
published (23).
Library Sequencing
Up to 12 final amplicon products were pooled together and
loaded, at 12pM concentration, on an Illumina MiSeq, using a
version 2 chemistry 2x250PE kit.
Data Analysis
The raw FastQ files are deposited at the Short Read Archive
(https://www.ncbi.nlm.nih.gov/sra) under accession number
SRP136075. Raw numbers of reads prior to subsampling are
provided in Supplementary Table 1. The FASTQ files produced
on the MiSeq were demultiplexed and UMI-corrected using an
analysis pipeline that incorporates Decombinator (19, 23–25). All
software is freely available at https://github.com/innate2adaptive/
Decombinator.
Typically, when analyzing TCR data, the total number of
TCRs in a sample are rarefied to either the minimum number
of TCRs from all samples (or lower), or an arbitrarily selected
percentage of the maximum read depth (usually 10%) of the
sample containing the largest number of TCRs. Motivated by
concerns over sample representation following rarefication, we
developed an algorithm to compute the minimum representative
subsampling depth for each sample (Supplementary Figure 1).
To begin, rarefication curves were drawn for each sample
between 100 and 1% of their total number of Decombinator-
identified reads (DCRs), computing the Gini coefficient and
Shannon entropy, normalized to their returned values at 100%
read depth, at each 1% interval. The total population of DCRs in
a sample was randomly subsampled 30 times for each iteration,
and the mean and standard error calculated. The algorithm then
computes the gradient of the mean normalized Gini coefficient
decline at each subsampling depth, recording each event where
the gradient >1.1, representing greater than linear depreciation
over time, but not low enough to include minor variation. As
the normalized Gini coefficient is bounded in x and y between
0 and 1, where subsampling will eventually tend toward a
single sequence, giving an even population, and a returned
Gini coefficient of 0, Gini coefficient was an ideal statistic to
quantify the effect of rarefication on. The percentages in x
where the gradient exceeded 1.1 were concatenated into arrays of
continuous integers, with an order statistic assigned to each array,
the lowest of which was selected. This assumes that the lowest
continuous sequence of gradients above 1.1 would represent the
point at which the distance between low frequency clonotypes
and the top clonotypes reduce, confounding the quantifiable
diversity in the sample. The largest subsampling value from this
list + 1 was selected (i.e., a 20% subsample value would become
21%) and is marked as the minimum subsampling depth for
that sample, the point just prior to where the gradient of mean
normalized Gini coefficient decline exponentially increases. The
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maximum subsampling depth of a sample is inherently defined
as equal to 100% of the DCRs identified in a sample. The
algorithm then optimizes the greatest number of samples that
can be included between their total number of DCRs, and their
minimum subsampling depth, from which, for this study, a
subsampling depth of 10,232 DCRs was determined.
Among the analyses applied to the data were two different
diversity metrics, Gini coefficient and Shannon entropy. Gini
coefficient is a measure of inequality, originally developed as an
economics tool for measuring wealth distribution. It is classically
defined as twice the area between the 45◦ -line and the Lorenz
curve (a curve visualizing cumulative abundance against the
cumulative population) for the data. The scale ranges between 0
and 1, where 0 = completely equal (x clones, all with identical
frequencies) and 1 = completely unequal (i.e., tending toward
sample oligoclonality). It can be used to gauge the inequality
of the frequency distribution between different clonotypes in
each sample, and give a summary of the clonotype abundance
distribution.
Shannon entropy, a separate measure, quantifies diversity
through the incorporation of both evenness and richness, with
higher values representing more even populations of TCR rich
samples. Shannon entropy,H(X), whereX is the CDR3 data from
a single sample, is defined as





b p (xi) (1)
where p(xi) is the proportional abundance of clonotype i and b is
the logarithm base of 2.
For analyses, the ineq package (version 0.2.13) was used in the
R environment (version 3.3.2) for computing the Gini coefficient
along with the vegan package (version 2.4.2) for computing
Shannon entropy. The ggplot2 package (version 2.2.1) was used
for all data visualizations. The subsampling algorithm and all
manual data analyses were executed using custom scripts written
in R. The Decombinator package v3.1 was executed using Python
(version 2.7.3). The beta chain for each sample was used unless
otherwise specified.
RESULTS
Abnormal Diversity Tends Toward
Normality Following CBT
We investigated TCR clonal distribution profiles using both
the Gini coefficient (a measure of inequality) and the Shannon
diversity index for all patients during immune reconstitution.
The results for beta chain are displayed below (Figure 1A).
We are able to demonstrate that the cord blood controls
have a Gini coefficient <0.2 and a Shannon diversity index
of >12. By contrast many of the post-CBT patient samples
exhibit higher Gini coefficients or lower Shannon diversity
index values indicating an abnormal TCR repertoire. Diversity
profiles are complex and exhibit multifactorial dependence on a
large number of covariates following transplantation. The TCR
repertoire becomes significantly more uneven (as demonstrated
by increased Gini, and decreased Shannon) post-transplant,
compatible with significant clonal expansion and repertoire
FIGURE 1 | (A) Plots of Gini Coefficient and Shannon Entropy against month
post-transplant; Diversity scores for control cord samples are shown on the
left hand side and patient samples on the right. Each line represents a different
patient. For comparison, adult control PBMC diversity histograms are
presented next to these plots, demonstrating a similar diversity distribution to
the control cord samples. (B) Frequency of most abundant 20 clonotypes as a
function of time shown for 4 patients (K, P, L, and F). Each color represents a
different clonotype. Lines between points represent a persistent clonotype
detected at multiple time points.
dysregulation. There is a trend toward a subsequent fall in Gini
index beyond 6 months post-transplant. However, the most
striking feature of the data is the variance in both indices,
both between and within patients, presumably reflecting major
dynamic changes in repertoire composition post-transplant. As
can be seen from Figure 1A, the majority of profiles exhibit
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trends toward normality over time, as defined by the diversity
shown in the control cord population. Adult control PBMC data
demonstrated a similar distribution of diversity values to control
cords. This made cord data an excellent stand-in for data from
age-matched control PBMCs. Patient O was the only patient
to require a second graft (due to disease relapse and dropping
chimerism) 6 months after the initial CBT. As can be seen, the
trajectory of their profile appears to be abnormal in comparison
with the other patient’s profiles. Figure 1B also displays the most
abundant 20 clonotypes as a percentage of total DCRs at different
timepoints for a selection of patients, demonstrating the dynamic
nature of the repertoire’s clonal composition during a patient’s
recovery.
Variance in TCR Diversity Is Inherently
Linked With Thymic Output
The levels of thymic output, as measured by TRECs, are low
in the initial stages of reconstitution, and then follow a non-
linear logistic growth dynamic which plateaus between 4 and 6
months, reflecting a limit on thymic export, and the generation
of new naïve TCRs (Figure 2A). As expected, the number of
naïve T cells in blood is correlated to the number of TRECs
(Figure 2B). Interestingly, the Gini index is inversely correlated
to the number of TRECs, presumably reflecting the increase
in repertoire diversity as more naïve cells enter the circulation
(Figure 2C).
GvHD and Cell Counts Are Correlated With
TCR Diversity, but not Cell Dose
To understand the relationship between TCR repertoire
reconstitution and the clinical parameters of reconstitution, we
examined the Gini index as a function of level of graft mismatch,
the conditioning regimen, the cell dosage per kg, severity of
graft vs. host disease (GvHD), the presence of post-transplant
infections, cell counts during reconstitution, and duration of any
post-transplant immunosuppression. Interestingly, we found
that diversity was inversely related to GvHD scores, suggesting
that GvHDmay be driving clonal expansions and hence reducing
clonal diversity (Figure 3A). No significant correlation could be
observed with any other clinical parameter. Specifically, we were
unable to see any influence of the CD3+ cell dose given in the
cord blood unit nor the conditioning regimen on diversity scores
(Figures 3B,C).
FIGURE 2 | (A) TREC numbers rise and then plateau following transplantation. A Spearman’s rank correlation coefficient test showed a partially monotonic
relationship between TREC numbers and time after transplant (rs = 0.407, p < < 0.01). The data was fitted by LOESS regression (blue line). Confidence intervals are
represented by the gray shaded area. Each point represents a single TREC count. (B) Naive T cell numbers correlate to TREC levels (rs = 0.611, p < < 0.01). (C)
Repertoire diversity, as represented by the Gini coefficient, reflects the replenishment of the peripheral naïve repertoire via thymic export. A cubic spline model was
fitted to the data, demonstrating the relationship between TRECs and TCR diversity (rs = −0.440, p < < 0.01).
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FIGURE 3 | (A) GvHD score extracted from clinical notes found to correlate
with TCR diversity (Gini coefficient) demonstrating a possible link between
degree of sample clonality and severity of GvHD [one way ANOVA (F = 7.582,
p = 0.00746)]. (B) The Gini coefficient as a function CD3 cell dose in the cord
blood unit [Spearman’s rank correlation coefficient (rs = 0.2086, p = 0.364)].
(C) No correlation was observed between the Gini coefficient and the
conditioning regimen following transplantation [Wilcoxon rank sum test (W =
221, p = 0.3791)]. MAC, myeloablative conditioning; RIC, reduced intensity
conditioning.
Verification of the Antigen Specificity
VDJdb (26) is an open-access TCR database that contains CDR3s
annotated for antigen specificity. We investigated whether
antigen specificity could be defined for the unique clonotypes in
each sample, using VDJdb. We found several examples of TCR
sequences from the database in the repertoires of the patients
in this study (Figure 4). These shared sequences are likely to
represent “public” TCRs which may have higher probabilities
of being generated owing to the non-uniform nature of the
recombination process (27). Unexpectedly, clonally expanded
HIV-1 “specific” sequences were found in each reconstituted
repertoire (ranging between 0.04–0.45% across all 16 CBT
patients), despite all patients being confirmed to be HIV negative
prior to transplantation. These observations suggest that the
antigen specific annotations of these sequences should be treated
with caution, as different pairing between alpha and beta chains,
and cross-reactivitymay both contribute to the antigen specificity
of individual cells.
Recovering and Quantifying Spectratyping
Classifications Using TCR Sequencing
The status of the reconstitution of the T cell compartment is
currently investigated, inter alia, by classifying the “normality”
of the repertoire using spectratyping. We investigated whether
similar classification could be carried out on the basis of the
TCR repertoire as assessed by NGS. Spectratypes are usually
assessed utilizing both the median number of peaks per TCRVβ
family and the number of TCRVβ families with a distribution
that take an approximate Gaussian form. On the basis of
these parameters, repertoires are assigned to three groups,
“Abnormal,” “Almost normal” and “Normal.” We compared the
abundance profile of two repertoires, classified by spectratyping
as “Abnormal” (taken from a patient three months post-
transplant) and “Normal” (taken from the same patient after
12 months) with a control cord sample (CBC) (Figures 5A,B).
The three repertoires can readily be differentiated from each
other. The 3 months “Abnormal” profile contains numerous
high abundance clonal expansions dominating a portion of
the TCR repertoire. The profile at 12 months is more evenly
distributed, lacks drastically overrepresented clonotypes, and
the overwhelming majority of sequences are observed <10
times. Similarly, the control cord sample, CBC, expresses a
comparable repertoire distribution to the spectratype-defined
“Normal” sample. We next plotted diversity metrics obtained
from all our samples, as a function of clinical spectratyping
score (Figure 5C). The Gini and Shannon index were both
significantly associated with spectratyping score (Kruskal-
Wallis test, p << 0.01), suggesting that the diversity of the
repertoire could contribute to immunophenotyping in assessing
T cell reconstitution following transplantation in children
(Figure 5C).
Finally, we reconstructed “virtual” spectratype profiles by
plotting the CDR3 length profile taken from the sequence
data, and compared this to spectratypes from the same profile.
A representative example of a “normal” and “abnormal”
spectratype sample are shown in Figure 6. The virtual profiles
were strikingly similar to those obtained by the classical protocol,
and clearly demonstrated the differences between normal and
abnormal repertories. However, the virtual spectratypes showed
greater resolution, and additionally allowed analysis via V region
subtype, which was not possible using the standard method.
Our NGS implementation emphasizes the dominance of specific
subfamilies in defining the distribution seen in a traditional
spectratype.
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FIGURE 4 | TCR sequences with previously described antigen-specific
annotation are observed in the repertoire of the reconstituting patients. The
plot shows a representative example of several annotated sequences in one
patient in relation to time post-transplant (eight target species from which
antigen peptide is derived is shown in Legend). Note that the patient was
confirmed to be HIV-1 negative.
DISCUSSION
We have developed a novel tool using NGS with an analytical
pipeline and diversity scoring metrics to accurately quantify TCR
diversity. We applied this to a cohort of patients undergoing
CBT and have presented several findings that could not
be seen using conventional TCR spectratyping techniques.
Spectratyping, the widely-adopted clinical gold standard for T
cell repertoire immunophenotyping, has been used since 1994
(28) with great success in monitoring the immune response,
especially in patients following transplantation. Despite the
technique’s popularity, there are clear limitations in the data it
produces, which stem from the era in-which it was developed.
Spectratyping data are low-resolution depictions of the TCR
repertoire, condensing complex immunological information
into singular points describing CDR3 length, frequency, and
associated gene. This inherently restricts the potential of the
biological information available for extraction with modern
methodologies. One pivotal issue is the lack of ability to
deconvolve the TCR V gene family distributions into their
clonotype constituents, which may or may not be made up of
multiple antigen-distinct clonotypes. An emerging methodology
that addresses these limitations is TCR repertoire sequencing,
such as the protocol utilized in this study (23). Other protocols
have been recently developed to quantitatively analyse the T cell
repertoire in patients post-HSCT, but this has so far been limited
to either adult recipients (29, 30), or restricted to beta chain
analysis only (29). In addition these studies had been carried out
on patients who had received HSCT as treatment for malignancy.
Both of these groups suggest that an early recovery of the TCR
repertoire diversity is likely to be linked with lower risks of both
GvHD and relapse, highlighting the clinical need to utilize this
technology to monitor patients following treatment. As far as
we are aware, this methodology has not yet been applied to
pediatric CBT recipients, and therefore there is little knowledge
on TCR clonotype composition and reconstitution dynamics in
this cohort.
In this study, we found that TCR diversity in children who
have received CBT is extremely heterogeneous both between
and within individual patients, reflecting both the clinical
background and the dynamics of the reconstitution process.
Thirteen of the sixteen patients in this study are alive and well.
Three patients died following disease relapse; patient A died 4
years post-CBT, patient C died 9 months post-CBT and patient J
died 14 months post-CBT.
The repertoire typically tends to return to normality between
6 and 12 months after transplantation, although this trend needs
to be confirmed in larger studies. We noticed one clear exception,
patient O, who by month 12 had not yet reconstituted a diverse
T cell receptor repertoire. This might be expected given that this
patient relapsed with JMML within the first 3 months following
CBT. They then received a subsequent CBT 6 months after their
first transplant.
We observed considerable variance in diversity aroundmonth
1 post-CBT which is likely determined by a combination of
three covariates: (1) the initial TCR repertoire in the patient,
constituted by the cell pool the patient is left with following
immune ablation, (2) the repertoire of the cord cell dose they are
administered, and (3) the short-term reaction of this repertoire
to the initial antigen landscape following transplantation.
Interestingly, the TCR data demonstrated dramatic variation
in the top 20 clonotypes expressed over time in patients post-
CBT. These data contrast with the typically stable profile seen
in healthy individuals, where comparatively little variation is
present over time in the top clonotypes (31).
We show that the initial repertoire is unlikely to derive from
recent thymic immigrants, since thymic output immediately
following transplantation is low. As reconstitution continues,
higher TREC levels correlate with an increased repertoire
diversity, as captured by the low Gini coefficient scores,
indicating thymic-dependent reconstitution of the naïve
repertoire post-CBT (21). A plateau for thymic export of naïve
T cells was observed between months 4 and 6, as reported
previously (32).
CBT is increasingly used in preference to BMT, due in-part to
the lower risk of acute and chronic GvHD.We observed that TCR
diversity is inversely correlated to GvHD scores. Clinically, less
diverse TCR profiles post-transplant may indicate the presence
of large, dominant, donor-derived but host-directed clonotypes.
There is significant interest in optimizing CD3+ cell dose in
the cord blood unit for driving healthy reconstitution. We
had hypothesized that CD3+ cell dose in the cord blood unit
would impact on diversity following CBT, but found no clear
relationship between these variables. Low patient numbers in
combination with the inherent stochasticity in the colonizing
process may be confounding any potential relationships. Studies
with larger patient numbers across the range of CD3+ cell doses
should be encouraged in order to investigate the impact of this
variable further.
Several studies have investigated the impact on disease
outcome between myeloablative (MAC) and reduced intensity
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FIGURE 5 | Changes in the abundance profile of CDR3 sequences reflect normalization of the repertoire. (A) A density plot showing the distribution of abundances for
the beta chain of CBT patient A, (left), 3 months after transplant, classified as abnormal by spectratyping, (middle) 12 months after transplant, classified as normal by
spectratyping, (right) and a control cord. At month 3, CDR3 frequency density profile is highly abnormal with an overrepresentation of clonal expansions. By month 12,
the repertoire becomes much more even reflecting a shift back towards normality. (B) A pie chart reflecting the same clonotype expression profile as (A), where color
represents clonotype frequency. (C) TCR repertoire diversity reproduces the repertoire classification determined by spectratyping. Gini coefficient (left) and Shannon
entropy (right) for each sample is plotted in relation to spectratyping classification.
(RIC) conditioning regimens ((33), the regimen’s effect
in transplantation-related morbidity, mortality, as well as
tolerance in older patients (34)). However, no evaluation
has ever been shown between conditioning and diversity in
pediatric CBT recipients. In this study, no correlation between
MAC/RIC and Gini coefficient was observed, indicating that
the conditioning alone is not driving immune reconstitution
following transplantation. The limitation of our patient group
size emphasizes the need for larger cohorts so that the many
confounders, together with conditioning, could be examined for
their affect in disease outcome.
In addition to these clinical investigations, we investigated the
clonal expansions seen in our CBT cohort by identifying antigen
“specific” sequences within our samples, using VDJdb. The
discovery of HIV-1 “specific” and clonally expanded sequences
in clinically verified HIV seronegative samples supports the
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FIGURE 6 | A “Normal” (A) PCR-derived spectratype from patient M and a “Abnormal” (B) PCR-derived spectratype from patient L (both 12 months post-transplant)
compared to reconstructed spectratypes from time-matched NGS data. Due to the resolution offered by the NGS data, we were able to separate the NGS-derived
spectratype into its constituent subfamilies.
theory of high levels of TCR cross-reactivity across the
repertoire. Given this finding, caution is advised over the
use of the term “specific” in relationship to specific TCR
sequences. An alternate and biologically appropriate method
for communicating the reactivity of an individual’s TCR
profile would be to refer to a sequence or profile’s “antigen
binding potential.” Recent publications, such as Emerson et al.
(35), have demonstrated that statistical signal is detectable in
CDR3 sequences expressed in an individual’s TCR repertoire,
and using this have developed a classification framework for
CMV diagnosis using immunosequencing of TCRβ molecules.
Antigen specificity may therefore more usefully be considered
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a property of a repertoire, rather than of a set of specific
sequences.
In conclusion, spectratyping remains the gold standard
in clinical assessment of the TCR repertoire. We were
able to verify the ability of NGS data to visualize clear
immunophenotyping differences between clinically distinct,
spectratyping-grouped patient samples. Furthermore, we were
able to quantify this effect using diversity metrics. This is
likely to be important in furthering our understanding of
the complex confounding effects on immune recovery of
conditioning regimen, source of hematological stem cells, cell
doses, post-transplant prophyllaxis, GvHD, GvL, and underlying
infection. We have now demonstrated a valuable new tool
for quantitative assessment of T cell repertoire recovery that
can utilized to improve our understanding of these effects.
In summary our study provides strong rationale for further
larger-scale prospective clinical trials, to establish the value of
incorporating TCR repertoire sequencing as a routine prognostic
or diagnostic test following pediatric hematological transplant.
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